<DOC>
	<DOC>NCT02989649</DOC>
	<brief_summary>The purpose of this study is to observe alogliptin and alogliptin fixed-dose combinations (FDCs) utilization patterns, as well as clinical response to treatment with alogliptin or alogliptin FDCs, in standard clinical practice.</brief_summary>
	<brief_title>Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice</brief_title>
	<detailed_description>The drug being studied in this study is called alogliptin and alogliptin FDCs. Alogliptin and alogliptin FDCs is being researched to treat people who have diabetes mellitus type 2. This study will look at the glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2. The study will enroll approximately 1199 patients. Alogliptin and alogliptin FDCs will be prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study). This multi-center study will be conducted in China and Hong Kong. The overall duration of study for observation will be approximately 6 months, or up to loss to follow-up or death, whichever occurs first. Participants will make multiple visits to the clinic as per regular doctor's appointments.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1. Has a diagnosis of T2DM. 2. Has made the decision, along with his/her treating physician, to begin treatment with alogliptin or alogliptin fixeddose combinations (FDCs). 3. Has an glycated hemoglobin (HbA1c) value recorded at most 3 months before initiation of treatment with alogliptin or alogliptin FDCs. 4. Alogliptin or alogliptin FDCs is prescribed according to the approved label for China and Hong Kong. 1. Has gestational diabetes or type 1 diabetes mellitus. 2. Has used Dipeptidyl peptidase4 inhibitors (DPPIV inhibitors) or Glucagon like peptide1 agonists (aGLP1) within the 3 months prior to the start of alogliptin or alogliptin FDCs treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>